Infectious Diseases (all articles)
Perspective: The race to make COVID antibody therapies cheaper and more potent
25 Oct, 2020 | 23:43h | UTCThe race to make COVID antibody therapies cheaper and more potent – Nature
Perspective: Why COVID outbreaks look set to worsen this winter
25 Oct, 2020 | 23:41h | UTCWhy COVID outbreaks look set to worsen this winter – Nature
Related: WHO warns of tough months ahead as COVID tops 42 million – CIDRAP
Perspective: COVID-19 can affect the heart
25 Oct, 2020 | 23:39h | UTCCOVID-19 can affect the heart – Science
Commentary from the author
https://twitter.com/EricTopol/status/1320427201351745536
Down syndrome tied to 10 times the risk of COVID-19 death
23 Oct, 2020 | 09:13h | UTCDown syndrome tied to 10 times the risk of COVID-19 death – CIDRAP
Original study: COVID-19 Mortality Risk in Down Syndrome: Results From a Cohort Study Of 8 Million Adults – Annals of Internal Medicine
Meta-analysis: Preventive malaria treatment among school-aged children in sub-Saharan Africa
25 Oct, 2020 | 23:22h | UTCCommentaries: Landmark Study Suggests Malaria-Preventive Drugs Dramatically Reduce Infections and Improve Health of School Children – University of Maryland AND Back to school for malaria prevention: a new tool in the era of malaria elimination? – The Lancet Global Health
Commentary on Twitter
Conclusion of a new systematic review and meta-analysis: "Preventive treatment of malaria among school-aged children reduces the burden of malaria in this age group and could be a key intervention to decrease P falciparum transmission…" https://t.co/UaNBdsKaze pic.twitter.com/82e1OMX7TF
— The Lancet Global Health (@LancetGH) October 23, 2020
Randomized trial: Convalescent plasma ineffective for patients hospitalized with Covid-19
23 Oct, 2020 | 09:15h | UTCEditorial: Convalescent plasma is ineffective for covid-19 – The BMJ
Commentary on Twitter
Just published @bmj_latest: A randomized trial of convalescent plasma for moderate covidhttps://t.co/dUvEMFSLHG
No benefit. It was underpowered to detect mortality reduction with 464 patients. A large RCT is needed to resolve the question, but these findings are not encouraging. pic.twitter.com/WGtz9IVSZe— Eric Topol (@EricTopol) October 23, 2020
A global survey of potential acceptance of a COVID-19 vaccine
23 Oct, 2020 | 09:11h | UTCA global survey of potential acceptance of a COVID-19 vaccine – Nature Medicine
Commentary: COVID Vaccine Hesitancy – Science-based Medicine
Pro/con debate: Therapeutic anticoagulation in hospitalized patients with Covid-19 without established thromboembolism
23 Oct, 2020 | 09:12h | UTCAnticoagulation in Hospitalized Patients with Covid-19 – New England Journal of Medicine
Related editorial: Anticoagulation in COVID-19: It Is Time for High-Quality Evidence – Journal of the American College of Cardiology
Coronavirus vaccine volunteer in Brazil’s AstraZeneca trial dies – but authorities say trial to continue
23 Oct, 2020 | 09:08h | UTCSee also: AstraZeneca COVID-19 vaccine trial Brazil volunteer dies, trial to continue – Reuters AND Expert reaction to media reports suggesting a person in Brazil who was taking part in the Brazil arm of the Oxford/AstraZeneca vaccine trial has died – Science Media Centre
Study: Low risk of SARS-CoV-2 transmission among coworkers in a surgical environment
23 Oct, 2020 | 09:05h | UTCRisk of SARS-CoV-2 Transmission Among Coworkers in a Surgical Environment – Mayo Clinic Proceedings
The false promise of herd immunity for COVID-19
23 Oct, 2020 | 09:03h | UTCThe false promise of herd immunity for COVID-19 – Nature
Study: COVID-19 is at least 5 times deadlier than flu for hospitalized patients
23 Oct, 2020 | 09:09h | UTCCOVID-19 is at least 5 times deadlier than flu for hospitalized patients – LiveScience
Commentary on Twitter
Patients hospitalized in @VeteransHealth facilities for #COVID19 were at higher risk for serious complications and death than those hospitalized for flu, a new MMWR report finds. Learn more: https://t.co/66ry7TJon4. pic.twitter.com/rCKMsVS03b
— CDC (@CDCgov) October 20, 2020
CDC expands definition of ‘close contacts,’ after study suggests Covid-19 can be passed in brief interactions
23 Oct, 2020 | 09:07h | UTC
Perspective: The engines of SARS-CoV-2 spread
23 Oct, 2020 | 09:02h | UTCThe engines of SARS-CoV-2 spread – Science
Amid pandemic, U.S. has seen 300,000 ‘excess deaths,’ with highest rates among people of color
22 Oct, 2020 | 09:41h | UTC
Commentary on Twitter
A new @CDCMMWR estimates since January 2020, 299,000 more people have died than the typical number during the same weeks in previous years. At least 2 out of 3 excess deaths were attributed to #COVID19. Learn more: https://t.co/fg4W6u4e3C. pic.twitter.com/i9TDxrBrTV
— CDC (@CDCgov) October 20, 2020
Randomized trial: Tocilizumab does not improve outcomes for patients hospitalized with Covid-19
22 Oct, 2020 | 09:42h | UTCEfficacy of Tocilizumab in Patients Hospitalized with Covid-19 – New England Journal of Medicine
New calculator predicts risk of hospital admission and mortality from coronavirus 19 in adults
22 Oct, 2020 | 09:37h | UTCSee calculator: QCovid® risk calculator
Commentary on Twitter
A new "living" high quality prediction model for #COVID19 risk for hospitalization and mortality: top 20% risk accounted for 94% of deaths; https://t.co/aPXRM2pHCq calculatorhttps://t.co/gdd8b3j33K @bmj_latest
by @AshClift @JuliaHCox @OxPrimaryCare and colleagues pic.twitter.com/s8TrWWECb0— Eric Topol (@EricTopol) October 21, 2020
SARS-CoV-2 immunity: Review and applications to phase 3 vaccine candidates
22 Oct, 2020 | 09:36h | UTCSARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates – The Lancet
Commentary: The COVID-19 vaccine pipeline – News Medical
Commentary on Twitter
NEW Review—G Poland, I Ovsyannikova & R Kennedy @MayoClinic discuss what is currently known about human humoral & cellular immune responses to SARS-CoV-2 & relate this knowledge to the #COVID19 vaccines currently in phase 3 clinical trials https://t.co/eDkFq4WStA pic.twitter.com/hfw6yjviym
— The Lancet (@TheLancet) October 14, 2020
Will Covid-19 vaccines save lives? Current trials aren’t designed to tell us
22 Oct, 2020 | 09:40h | UTCWill covid-19 vaccines save lives? Current trials aren’t designed to tell us – The BMJ
Commentaries: COVID-19 vaccine trials won’t tell us if the shots save lives, expert notes – CNN AND Coronavirus vaccine trials won’t tell us if they save lives, prevent serious illness or stop transmission – here’s why – The Conversation
Commentary on Twitter
The world is waiting on a vaccine for covid-19 that will reduce the likelihood of getting severely ill and prevent infection. Yet the current phase III trials are not actually set up to prove either, finds Peter Doshi https://t.co/BSb9WiUQXo
— The BMJ (@bmj_latest) October 21, 2020
Perspective: Immunity and Re-Infection
22 Oct, 2020 | 09:34h | UTCImmunity and Re-Infection – Science Translational Medicine
Video consultations in primary and specialist care during the covid-19 pandemic and beyond
21 Oct, 2020 | 09:30h | UTCVideo consultations in primary and specialist care during the covid-19 pandemic and beyond – The BMJ
Studies offer little hope for Tocilizumab in treating COVID
21 Oct, 2020 | 09:27h | UTCStudies offer little hope for tocilizumab in treating COVID – CIDRAP
See studies: Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 – JAMA Internal Medicine AND Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial – JAMA Internal Medicine AND Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial – JAMA Internal Medicine
Commentary: expert reaction to three studies of Tocilizumab to treat COVID patients – Science Media Centre
Related study (preprint): Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia – medRxiv
Dozens to be deliberately infected with coronavirus in UK ‘human challenge’ trials
21 Oct, 2020 | 09:25h | UTCDozens to be deliberately infected with coronavirus in UK ‘human challenge’ trials – Nature
Commentaries: U.K. Preparing COVID-19 Vaccine Trials That Deliberately Expose Study Subjects – NPR AND UK plan to be first to run human challenge Covid trials – BBC
Viewpoint – COVID-19, children and non-communicable diseases: Translating evidence into action
21 Oct, 2020 | 09:19h | UTC
Commentary on Twitter
"The recognition that NCDs are a massive contributor to COVID-19 mortality and severe illness across all age groups should be a wake-up call to accelerate preventive strategies for NCDs."
New piece on how children & youth are affected by #COVID19 & #NCDshttps://t.co/oXV6UAdgGL pic.twitter.com/WNTZtVAztZ
— Marie Hauerslev (@HauerslevMarie) October 17, 2020
Studies point to big drop in COVID-19 death rates
21 Oct, 2020 | 09:23h | UTCStudies Point To Big Drop In COVID-19 Death Rates – NPR